Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BioMS Technology Corp.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male of female subjects, 18-65 years of age with a diagnosis of SPMS
HLA DR2 and/or DR4 positive
Absence of a relapse in the 3 months prior to baseline
EDSS of 3.0 - 6.5
You may not be if
Therapy with Beta-interferon, glatiramer acetate within 3 months or mitoxantrone, cyclophosphamide, methotrexate, azathioprine or any immune modulating or immunosuppressive drugs within 6 months of baseline
Treatment with Tysabri within 2 years of baseline
Females who are breast feeding, pregnant (pregnancy test at baseline) or not using a medically approved method of contraception regularly
Clareo Health | Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
